Keywords: مهار کننده یونیز کیناز; Janus kinase inhibitor; Myelofibrosis; Pulmonary cryptococcosis; Pulmonary nodules; Ruxolitinib; CT; computed tomography; IL; interleukin; JAK; Janus kinase; TNF; tumor necrosis factor;
مقالات ISI مهار کننده یونیز کیناز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده یونیز کیناز; atopic dermatitis; Janus kinase inhibitor; tofacitinib; AD; atopic dermatitis; IL; interleukin; JAK; Janus kinase; QoL; quality of life; SCORAD; Scoring of Atopic Dermatitis; STAT; signal transducer and activator of transcription; Th2; type 2 helper T-cel
Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates
Keywords: مهار کننده یونیز کیناز; Janus kinase inhibitor; Mycophenolate mofetil; Tacrolimus; Non-human primate; Renal transplantation;
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
Keywords: مهار کننده یونیز کیناز; immune response; Janus kinase inhibitor; pneumococcal vaccine; T cell; tetanus toxoid; tofacitinib; CI; confidence interval; ELISA; enzyme-linked immunosorbant assay; GMFR; geometric mean fold rise; JAK; Janus kinase; LTE; long-term extension; OPA; opsono
Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats
Keywords: مهار کننده یونیز کیناز; Baricitinib; Carcinogenicity; Janus kinase inhibitor; Rats; Tg.rasH2 mice;
How is the Ph-like signature being incorporated into ALL therapy?
Keywords: مهار کننده یونیز کیناز; Acute lymphoblastic leukemia; Philadelphia chromosome-like; tyrosine kinase inhibitor; Janus kinase inhibitor; Imatinib; Dasatinib; Ruxolitinib;
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
Keywords: مهار کننده یونیز کیناز; Asia; Janus kinase inhibitor; Tofacitinib; Plaque psoriasis; Efficacy; Safety;
Discovery of tricyclic dipyrrolopyridine derivatives as novel JAK inhibitors
Keywords: مهار کننده یونیز کیناز; Janus kinase inhibitor; IL-2; Organ transplant rejection; Autoimmune diseases; Immunomodulator;
Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation
Keywords: مهار کننده یونیز کیناز; Alkali burn; Corneal inflammation; Janus kinase inhibitor; Small molecule drug; Tofacitinib;
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Keywords: مهار کننده یونیز کیناز; efficacy; Janus kinase inhibitor; long-term; psoriasis; randomized controlled trial; safety; tofacitinib; AE; adverse event; BID; twice daily; CI; confidence interval; HZ; herpes zoster; IR; incidence rate; LTE; long-term extension; NMSC; nonmelanoma skin
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases
Keywords: مهار کننده یونیز کیناز; costs; Janus kinase inhibitor; real-world experience; rheumatoid arthritis; tofacitinib; treatment patterns;
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Keywords: مهار کننده یونیز کیناز; Acute myelogenous leukemia; Clinical study; JAK2V617 mutation; Janus kinase inhibitor; Myelofibrosis; Ruxolitinib
Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors
Keywords: مهار کننده یونیز کیناز; Janus kinase inhibitor; IL-2; Organ transplant rejection; Autoimmune diseases; Immunomodulator;
Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells
Keywords: مهار کننده یونیز کیناز; Janus kinase inhibitor; STAT3; Hepatocellular carcinoma; TRAIL-induced apoptosis; S phase cell-cycle arrest